Sign In

Prashant Warier

Co-Founder & CEO at Qure.ai

Prashant Warier is the Co-Founder and CEO of Qure.ai, a global healthcare AI company that uses deep learning to automatically interpret X-rays, CT scans, and MRIs.12 He holds a Ph.D. and MS in Operations Research from Georgia Institute of Technology and a BTech from IIT Delhi.2

Warier has an extensive background in artificial intelligence and data science. Before founding Qure.ai, he worked as the Chief Data Scientist at Fractal Analytics.2 He also founded an adtech company that was later acquired by Fractal.3

Under Warier's leadership, Qure.ai has achieved significant milestones:

  1. The company recently secured $65 million in Series D funding to expand into the US and other markets.1
  2. Qure.ai's AI solutions are used in over 90 countries and 3,000 sites, addressing critical conditions like tuberculosis, lung cancer, and stroke.5
  3. The company has processed over 1.2 crore (12 million) patients and is projected to handle about 60 lakh (6 million) patients this year alone.4

Warier is passionate about using AI to make healthcare more accessible and affordable worldwide.5 He has been recognized for his work, receiving the Forbes Leadership Award for exemplary work during the COVID-19 pandemic.6

Highlights

Aug 22 · linkedin

Thrilled to share that Qure.ai’s Chest CT AI tool, qCT LN Quant, has received FDA clearance! This cutting-edge AI tool is set to revolutionize lung cancer care by enabling precise tracking of lung nodules on Chest CTs over time. Coupled with qXR-LN for Chest X-ray nodule detection and qTrack for follow-up management, it significantly enhances our lung cancer portfolio, driving early detection and improved patient outcomes. Join us at #AABIP 2024 in North Carolina to witness how our AI solutions are reshaping medical imaging. With 16 FDA clearances, Qure.ai is committed to enhancing patient care globally! Learn more here: https://lnkd.in/dpqF4qnj

Jul 19 · linkedin

Proud to share that we have screened more than 2.5 million patients for Lung Cancer in partnership with AstraZeneca across Asia, Latin America, Africa and Europe.

Never imagined that we would reach this scale when we started working with Pei-Chieh Fong, Nipun Jain & Nick Passey潘尼克 back in 2020. This would not have happened without passionate team members from both AstraZeneca and Qure.ai who have worked diligently towards enabling an opportunistic pathway on Chest X-rays to diagnose lung cancer (LC) which can enable early LC diagnosis with limited additional investment.

https://lnkd.in/g_bHn8kh

Ti Hwei How, Kevin Sirjuesingh, Mohammed Hannan, Viraj Rajadhyaksha, Susan Mccutcheon, Sabine Luciani, Andrea Harvey, Ashwini Saha, Tuna Taş,MBA,PMP®,ITIL, Dr. Anil Kukreja, Subhankar Basak, PhD, Dr Ajaykumar Sharma, Esra Erkomay, Svetlana Yanchuk, Deepak Arora

Bhargava Reddy, Sagar Sen, Ketaki Kakade, Akhilesh D S N

Related Questions

What inspired Prashant Warier to start Qure.ai?
How did Prashant Warier's background in operations research influence his approach to AI in healthcare?
What are some of the biggest challenges Prashant Warier has faced in developing AI for radiology?
How has Qure.ai's technology evolved since its inception?
What are Prashant Warier's future plans for Qure.ai?
Prashant Warier
Prashant Warier, photo 1
Prashant Warier, photo 2
Add to my network

Location

Mumbai, Maharashtra, India